Literature DB >> 31388107

Combining epigenetic and immune checkpoint inhibitors in bladder cancer.

Clemens Thoma1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31388107     DOI： 10.1038/s41585-019-0221-3

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  4 in total

1.  Enhancing response to immunotherapy in urothelial carcinoma by targeted inhibition of the histone methyltransferase G9a pathway.

Authors:  Denzel Zhu; Emily Barry; Alexander I Sankin
Journal:  Transl Androl Urol       Date:  2019-12

2.  Development and validation of a molecular prognostic index of bladder cancer based on immunogenomic landscape analysis.

Authors:  Ning Xu; Zhi-Bin Ke; Xiao-Dan Lin; Ye-Hui Chen; Yu-Peng Wu; Yu Chen; Ru-Nan Dong; Shao-Hao Chen; Xiao-Dong Li; Yong Wei; Qing-Shui Zheng; Yun-Zhi Lin; Xue-Yi Xue
Journal:  Cancer Cell Int       Date:  2020-07-11       Impact factor: 5.722

3.  Modified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer-A Retrospective Digital Pathology Study.

Authors:  Uwe Bieri; Lorenz Buser; Marian Severin Wettstein; Daniel Eberli; Karim Saba; Holger Moch; Thomas Hermanns; Cédric Poyet
Journal:  Diagnostics (Basel)       Date:  2022-06-01

4.  Can Smoking Cause Differences in Urine Microbiome in Male Patients With Bladder Cancer? A Retrospective Study.

Authors:  Wenchao Ma; Wentao Zhang; Liliang Shen; Ji Liu; Fuhang Yang; Niraj Maskey; Hong Wang; Junfeng Zhang; Yang Yan; Xudong Yao
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.